As we approach the Thanksgiving meal, Dana-Farber nutritionists offer some easy tips for enjoying the holiday without packing on pounds. The average Thanksgiving dinner contains at least 3,000 calories. When you add in snacks, appetizers, and drinks throughout the day, you may end up consuming approximately 4,500 calories (two to three times what you may normally eat). Although this is only one meal, excess calories from a holiday season are unhealthy in the long run, as obesity is a risk factor for cancer.
While other kinds of cancer may receive more public attention, lung cancer remains the leading cause of cancer deaths. There are two main types of lung cancer: small cell carcinoma and non-small cell carcinoma, both of which mainly affect people over 45 years old. We spoke with Bruce E. Johnson, MD about causes and treatment options.
On Thanksgiving Day every year, Marc Kutzer and his sister, Roberta Klein, have much to be thankful for. In 2001, Kutzer went to his primary care physician for a routine physical. What his doctor discovered led Kutzer, 52, to Dana-Farber — and to a procedure he credits for saving not only his life, but also his sister’s.
With Brigham and Women’s Hospital and Boston Children’s Hospital, Dana-Farber has performed thousands of stem cell/bone marrow transplants for adult and pediatric patients with blood cancers and other serious illnesses. What’s the difference between these two terms? As it turns out, the only real distinction is in the method of collecting the stem cells. Let’s start with the basics.
Cancer scientists use a wide variety of techniques to study the growth and development of tumor cells. Laboratory research often focuses on individual cells or tissue samples, but to learn how cancers grow and respond to therapies in living organisms, scientists rely on other experimental models. In recent years, zebrafish have become the model of choice for studying many cancer types. Dana-Farber’s A. Thomas Look, MD, who uses zebrafish in his own work, explains why.
Aromatase inhibitors (AIs), such as Arimidex, Aromasin, and Femara, have proven to be more effective than previous hormonal treatments for treating both early and advanced breast cancer in post-menopausal women whose tumors are dependent on estrogen. Compared with tamoxifen, these drugs are less likely to cause blood clots or raise the risk of endometrial cancer. As a result, AIs are used both in patients with early breast cancer and in those with metastatic disease.